^
    3d
    Lifting the Lid on Best Practice in a Case of Oligometastatic Breast Cancer. (PubMed, Clin Oncol (R Coll Radiol))
    We discuss the case literature on the management of ophthalmic and eyelid metastases, including the role of radiotherapy. We outline the multi-disciplinary team (MDT) discussions and recommendations made in the present case, which ultimately found that the risks of radiation toxicity would outweigh the benefits. Adjuvant therapy with fulvestrant and palbociclib was recommended, with future consideration of a CDK 4/6 inhibitor in the event of metastatic recurrence.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • EGFR positive
    |
    Ibrance (palbociclib) • fulvestrant
    3d
    Efficacy of CDK4/6 Inhibitor Plus Aromatase Inhibitor versus Fulvestrant in Chinese Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Advanced Breast Cancer. (PubMed, Breast Cancer (Dove Med Press))
    In general, both AI and FUL combinations are effective alternatives, irrespective of the CDK4/6i treatment line, liver metastasis at first relapse, or endocrine sensitivity. Further studies are expected.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    fulvestrant
    5d
    ACSS2-mediated metabolic-epigenetic crosstalk drives Fulvestrant resistance and represents a novel therapeutic target. (PubMed, NPJ Breast Cancer)
    In a therapy-resistant xenograft model, combination treatment reduced Fulv-dependent metastatic burden. These findings establish ACSS2 as a driver of endocrine resistance through nuclear acetyl-CoA provision for epigenetic reprogramming, representing a novel therapeutic target in metastatic breast cancer.
    Journal
    |
    ER (Estrogen receptor) • ACSS2 (Acyl-CoA Synthetase Short Chain Family Member 2)
    |
    fulvestrant
    6d
    RIGHT: Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males (clinicaltrials.gov)
    P1, N=30, Recruiting, Northwestern University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    fulvestrant • anastrozole
    6d
    PreEMBER: A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (clinicaltrials.gov)
    P2, N=600, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative
    |
    tamoxifen • Inluriyo (imlunestrant) • goserelin acetate
    7d
    ELENI: Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, iOMEDICO AG | Not yet recruiting --> Recruiting | Trial completion date: Jul 2029 --> Jun 2028
    Enrollment open • Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    Orserdu (elacestrant)
    7d
    The ESR1-MYH14 axis functions as a critical driver of cervical cancer progression and metastasis. (PubMed, Transl Oncol)
    The ESR1-MYH14 signaling axis drives cervical cancer growth and metastasis. Targeting this pathway may represent a promising therapeutic strategy for cervical cancer management.
    Journal
    |
    ER (Estrogen receptor) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MMP9 (Matrix metallopeptidase 9)
    |
    Etcamah (camizestrant)
    14d
    A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Shanghai Best-Link Bioscience, LLC
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    15d
    Standardized Analytical Verification of ctDNA ESR1 Mutation Testing in Metastatic HR+/HER2- Breast Cancer: A European Multicentre Study Using dPCR and NGS-Based Liquid Biopsy. (PubMed, Mol Diagn Ther)
    These results demonstrate that both dPCR and NGS-based liquid biopsy workflows can be successfully implemented for ESR1 mutation testing in routine clinical practice using locally validated assays. This multicentre verification study provides practical guidance on assay verification, DNA input requirements, and key analytical parameters required to ensure reliable ESR1 mutation detection across different European laboratories. Robust analytical verification of ESR1 testing may improve diagnostic reliability and support personalized treatment strategies for patients with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Journal • Liquid biopsy • Next-generation sequencing • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HR positive • HER-2 negative • HER-2 mutation • ESR1 mutation • HR positive + HER-2 negative • HER-2 negative + HR positive + ESR1 mutation
    |
    Orserdu (elacestrant)
    15d
    RIGHT: Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Northwestern University | N=75 --> 30
    Enrollment change
    |
    fulvestrant • anastrozole
    17d
    SERENA-2: A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (clinicaltrials.gov)
    P2, N=240, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2026 --> Jun 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    fulvestrant • Etcamah (camizestrant)
    17d
    SERAFA-1: A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=150, Not yet recruiting, AstraZeneca
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    Kisqali (ribociclib) • Etcamah (camizestrant)